![Elena Ridloff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elena Ridloff
Financieel Directeur/CFO bij
SIONNA THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-05-2026
Profiel
Mevrouw Elena H. Ridloff, CFA, is een Onafhankelijk Bestuurder bij Kymera Therapeutics, Inc., een Onafhankelijk Bestuurder bij Kronos Bio, Inc. en een Chief Financial Officer & Executive Vice President bij ACADIA Pharmaceuticals, Inc. Zij zetelt in de Raad van Bestuur van Kymera Therapeutics, Inc. en Kronos Bio, Inc. Mevrouw Ridloff was voordien werkzaam als Vice President-Investor Relations bij Alexion Pharmaceuticals, Inc, als Chief Executive Officer & Managing Member bij BioVision, Inc, als Senior Analyst bij Maverick Capital Ltd, en als Senior Analyst bij Paramount BioCapital Asset Management, Inc. Zij behaalde haar doctorale graad aan de Universiteit van Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-04-2026 | 38.532 ( 0,09% ) | 2 M $ | 31-05-2026 |
Actieve functies van Elena Ridloff
| Bedrijven | Functie | Begin |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Directeur/Bestuurslid | 12-03-2021 |
| SIONNA THERAPEUTICS, INC. | Financieel Directeur/CFO | 01-01-2021 |
Eerdere bekende functies van Elena Ridloff
| Bedrijven | Functie | Einde |
|---|---|---|
| KRONOS BIO, INC. | Directeur/Bestuurslid | 20-06-2025 |
| ACADIA PHARMACEUTICALS INC. | Financieel Directeur/CFO | 10-09-2021 |
| ALEXION PHARMACEUTICALS, INC. | Investor Relations Contact | 01-03-2018 |
BioVision, Inc.
 BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Algemeen Directeur | 01-04-2014 |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Analyst-Equity | 01-01-2012 |
Opleiding van Elena Ridloff
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
95
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Paramount BioCapital Asset Management manages hedge funds and private equity funds that focus on investments in healthcare and life sciences companies. The firm invests globally, with emphasis on the stocks of small-cap healthcare technology companies. | Finance |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Finance |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Stealth BioTherapeutics, Inc.
 Stealth BioTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat the mitochondrial dysfunctions and age-related diseases | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
